Heterogeneity at the HLA-DRB1 allelic variation locus does not influence multiple sclerosis disease severity, brain atrophy or cognition

Multiple Sclerosis Journal

Volumn 17, Issue 3, 2011, Pages 344-352

  Van Der Walt, Anneke ^a,b,e   Stankovich, J ^d   Bahlo, M ^c   Taylor, B V ^d   Van Der Mei, Iaf ^d   Foote, S J ^c   Rubio, J P ^b   Kilpatrick, T J ^b   Butzkueven, H ^a,b,e  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d UNIVERSITY OF TASMANIA   (Australia)

^e BOX HILL HOSPITAL   (Australia)

Author keywords

1501, multiple sclerosis; brain atrophy; cognition; HLA DRB1; severity

Indexed keywords

HLA DR ANTIGEN;

ADULT; ALLELE; ARTICLE; AUSTRALIA; BRAIN ATROPHY; COGNITION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE; ONSET AGE; SCORING SYSTEM;

EID: 79953183060     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458510389101     Document Type: Article

References (37)

1. Lincoln MR, Montpetit A., Cader MZ, et al. A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis. Nat Genet 2005 ; 37: 1108-1112. (Pubitemid 41486664)
2. Sawcer S., Ban M., Maranian M., et al. A high-density screen for linkage in multiple sclerosis. Am J Hum Genet 2005 ; 77: 454-467. (Pubitemid 41192651)
3. Kurtzke J. Rating neurological impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983 ; 33: 1444-1452. (Pubitemid 14237132)
4. Roxburgh RH, Seaman SR, Masterman T., et al. Multiple sclerosis severity score: Using disability and disease duration to rate disease severity. Neurology 2005 ; 64: 1144-1151.
5. Weatherby SJ, Thomson W., Pepper L., et al. HLA-DRB1 and disease outcome in multiple sclerosis. J Neurol 2001 ; 248: 304-310. (Pubitemid 32323869)
6. Hensiek AE, Sawcer SJ, Feakes R., et al. HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis. J Neurol Neurosurg Psychiatry 2002 ; 72: 184-187.
7. Masterman T., Ligers A., Olsson T., Andersson M., Olerup O. and Hillert J. HLA-DR15 is associated with lower age at onset in multiple sclerosis. Ann Neurol 2000 ; 48: 211-219. (Pubitemid 30617040)
8. Celius EG, Harbo HF, Egeland T., Vartdal F., Vandvik B. and Spurkiand A. Sex and age at diagnosis are correlated with the HLA-DR2, DQ6 haplotype in multiple sclerosis. J Neurol Sci 2000 ; 178: 132-135.
9. Smestad C., Brynedal B., Jonasdottir G., et al. The impact of HLA-A and -DRB1 on age at onset, disease course and severity in Scandinavian multiple sclerosis patients. Eur J Neurol 2007 ; 14: 835-840. (Pubitemid 47108189)
10. Villoslada P., Barcellos LF, Rio J., et al. The HLA locus and multiple sclerosis in Spain. Role in disease susceptibility, clinical course and response to interferon-beta. J Neuroimmunol 2002 ; 130: 194-201. (Pubitemid 35240007)
11. Barcellos LF, Oksenberg JR, Begovich AB, et al. HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am J Hum Genet 2003 ; 72: 710-716. (Pubitemid 36255969)
12. Barcellos LF, Sawcer S., Ramsay PP, et al. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum Mol Genet 2006 ; 15: 2813-2824. (Pubitemid 44400408)
13. Wu J-S., Qiu W., Castley A., et al. Modifying effects of HLA-DRB1 allele interactions on age at onset of multiple sclerosis in Western Australia. Mult Scler 2010 ; 16: 15-20.
14. Stankovich J., Butzkueven H., Marriott M., et al. HLA-DRB1 associations with disease susceptibility and clinical course in Australians with multiple sclerosis. Tissue Antigens 2009 ; 74: 17-21.
15. Dyment DA, Herrera BM, Cader MZ, et al. Complex interactions among MHC haplotypes in multiple sclerosis: susceptibility and resistance. Hum Mol Genet 2005 ; 14: 2019-2026. (Pubitemid 41418037)
16. DeLuca GC, Ramagopalan SV, Herrera BM, et al. An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locus. Proc Natl Acad Sci U S A 2007 ; 104: 20896-20901.
17. Olerup O., Hillert J., Fredrikson S., et al. Primarily chronic progressive and relapsing/remitting multiple sclerosis: two immunogenetically distinct disease entities. Proc Natl Acad Sci U S A 1989 ; 86: 7113-7117. (Pubitemid 19240875)
18. Weinshenker BG, Santrach P., Bissonet AS, et al. Major histocompatibility complex class II alleles and the course and outcome of MS: A population-based study. Neurology 1998 ; 51: 742-747. (Pubitemid 28449253)
19. McDonnell GV, Mawhinney H., Graham CA, Hawkins SA and Middleton D. A study of the HLA-DR region in clinical subgroups of multiple sclerosis and its influence on prognosis. J Neurol Sci 1999 ; 165: 77-83. (Pubitemid 29298086)
20. Butzkueven H., Kolbe S., Jolley D., et al. Evaluation of linear cerebral atrophy markers in multiple sclerosis. J Clin Neurosci 2008 ; 15: 130-137.
21. Parmenter BA, Weinstock-Guttman B., Garg N., Munschauer F. and Benedict RH Screening for cognitive impairment in multiple sclerosis using the Symbol Digit Modalities Test. Mult Scler 2007 ; 13: 52-57. (Pubitemid 46152761)
22. van der Walt A., Stankovich J., Bahlo M., et al. Apolipoprotein genotype does not influence MS severity, cognition, or brain atrophy. Neurology 2009 ; 73: 1018-1025.
23. Confavreux C. and Vukusic S. Natural history of multiple sclerosis: A unifying concept. Brain 2006 ; 129: 606-616. (Pubitemid 43278223)
24. de la Concha EG, Arroyo R., Crusius JB, et al. Combined effect of HLA-DRB1*1501 and interleukin-1 receptor antagonist gene allele 2 in susceptibility to relapsing/ remitting multiple sclerosis. J Neuroimmunol 1997 ; 80: 172-178. (Pubitemid 28015338)
25. Poser CM, Paty DW, Scheinberg L., et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983 ; 13: 227-231. (Pubitemid 13158528)
26. Hensiek AE, Seaman SR, Barcellos LF, et al. Familial effects on the clinical course of multiple sclerosis. Neurology 2007 ; 68: 376-383. (Pubitemid 46184215)
27. Runmarker B., Martinsson T., Wahlstrom J. and Andersen O. HLA and prognosis in multiple sclerosis. J Neurol 1994 ; 241: 385-390. (Pubitemid 24172335)
28. Cournu-Rebeix I., Genin E., Leray E., et al. HLA-DRB1*15 allele influences the later course of relapsing remitting multiple sclerosis. Genes Immun 2008 ; 9: 570-574.
29. Guerrero AL, Laherran E., Gutierrez F., et al. Apolipoprotein E genotype does not associate with disease severity measured by Multiple Sclerosis Severity Score. Acta Neurol Scand 2008 ; 117: 21-25. (Pubitemid 350264504)
30. Okuda DT, Srinivasan R., Oksenberg JR, et al. Genotype-phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures. Brain 2009 ; 132: 250-259.
31. Barkhof F., Calabresi PA, Miller D. and Reingold SC Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol 2009 ; 5: 256-266.
32. De Stefano N., Matthews P., Filippi M., et al. Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology 2003 ; 60: 1157-1162. (Pubitemid 36418778)
33. Zivadinov R., Uxa L., Zacchi T., et al. HLA genotypes and disease severity assessed by magnetic resonance imaging findings in patients with multiple sclerosis. J Neurol 2003 ; 250: 1099-1106. (Pubitemid 37152560)
34. Zivadinov R., Uxa L., Bratina A., et al. HLA-DRB1*1501, -DQB1*0301, -DQB1*0302, -DQB1*0602, and -DQB1* 0603 alleles are associated with more severe disease outcome on MRI in patients with multiple sclerosis. Int Rev Neurobiol 2007 ; 79: 521-535.
35. Fischer JS, Rudick RA, Cutter GR and Reingold SC The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler 1999 ; 5: 244-250. (Pubitemid 29405620)
36. Benedict RHB, Duquin JA, Jurgensen S., et al. Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire. Mult Scler 2008 ; 14: 940-946.
37. Wu J-S., James I., Qiu W., et al. HLA-DRB1 allele heterogeneity influences multiple sclerosis severity as well as risk in Western Australia. J Neuroimmunol 2010 ; 219: 109-113.